Is Mesoblast (ASX:MSB) Cheap Following Its Stronger Full Year Earnings?

What Mesoblast’s latest earnings tell you about the business

Mesoblast (ASX:MSB) has attracted fresh attention after reporting full year 2026 results on 26 August, with revenue of US$120.25 million and a reduced net loss of US$57.5 million compared with the prior year.

For investors watching Mesoblast stock, the combination of higher reported revenue and a smaller loss per share, both basic and diluted, puts the company’s regenerative medicine pipeline and funding needs back in focus.

Mesoblast’s latest numbers have arrived alongside a strong 30 day share price return of 16.75% and a 90 day share price return of 17.33%. The stock is still down 14.44% year to date, which leaves short term momentum improving against a backdrop of a very large 3 year total shareholder return of 4.43x.

Compare Mesoblast’s earnings shift with other potential breakouts by scanning our hand picked list of 12 high quality undiscovered gems across the market.

After a sharp 3 year rerating and a recent 30 day jump, the question for Mesoblast now is whether most of the easy upside is already reflected in the price or if the latest earnings reset leaves more on the table.

Most Popular Narrative: 21% Undervalued

Mesoblast’s most followed narrative puts fair value at A$3.00 per share compared with the last close of A$2.37, which frames this pricing gap as a key part of the story behind the latest earnings.

While increasing rates of chronic low back pain and the urgency to reduce opioid use create a large potential market for rexlemestrocel L, any setback in the confirmatory Phase III trial or slower than expected adoption by pain specialists could defer expected revenue inflection and prolong operating losses.

Read the complete narrative. Read the complete narrative.

Curious what assumptions sit behind that A$3.00 fair value for Mesoblast. The narrative leans on rapid revenue expansion, a sharp margin shift and a future earnings multiple that compresses meaningfully from today. The key is how those three ingredients interact over time.

Result: Fair Value of A$3.00 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors in Mesoblast still need to weigh the risk that Ryoncil adoption stays concentrated in a narrow pediatric niche, and that ongoing trials face delays or underwhelming outcomes.

Find out about the key risks to this Mesoblast narrative.

Another view on Mesoblast’s valuation

Mesoblast’s story so far leans on a fair value of A$3.00, yet the current A$2.37 share price also implies a rich P/S ratio of 18.2x. That is higher than the Australian Biotechs industry at 17.9x and well above a fair ratio estimate of 10.6x.

Compared with closer peers on 30x P/S, Mesoblast looks cheaper on one side and stretched on the other. The gap between today’s 18.2x and the 10.6x fair ratio highlights real valuation risk if sentiment cools. The key question is which reference point you trust most when sizing your exposure.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

After weighing the mixed signals around Mesoblast, it helps to move quickly and test the numbers against your own expectations. To understand what the current optimism is based on, take a closer look at the company’s 3 key rewards

Looking for more investment ideas beyond Mesoblast?

If Mesoblast has sharpened your focus, use that momentum. The right screen can surface opportunities you might otherwise overlook, and you do not want to miss them.

• Target potential value opportunities early by scanning our 12 high quality undervalued stocks to find companies that combine quality fundamentals with appealing pricing signals.
• Strengthen your portfolio’s foundation by reviewing the list of solid balance sheet and fundamentals (22 results) so you can focus on companies with sturdier financial footing.
• Dial back potential volatility by assessing the 14 resilient stocks with low risk scores to see which stocks align better with a more measured risk profile.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com